tetano
Editor, Senior Moderator
Sci Rep
. 2023 Feb 14;13(1):2599.
doi: 10.1038/s41598-023-29654-1.
Pulmonary recovery from COVID-19 in patients with metabolic diseases: a longitudinal prospective cohort study
Thomas Sonnweber[SUP] #[/SUP][SUP] 1 [/SUP], Philipp Grubwieser[SUP] #[/SUP][SUP] 2 [/SUP], Alex Pizzini[SUP] 2 [/SUP], Anna Boehm[SUP] 2 [/SUP], Sabina Sahanic[SUP] 2 [/SUP], Anna Luger[SUP] 3 [/SUP], Christoph Schwabl[SUP] 3 [/SUP], Gerlig Widmann[SUP] 3 [/SUP], Alexander Egger[SUP] 4 [/SUP], Gregor Hoermann[SUP] 4 5 [/SUP], Ewald Wöll[SUP] 6 [/SUP], Bernhard Puchner[SUP] 2 7 [/SUP], Susanne Kaser[SUP] 8 [/SUP], Igor Theurl[SUP] 2 [/SUP], Manfred Nairz[SUP] 2 [/SUP], Piotr Tymoszuk[SUP] 9 [/SUP], Günter Weiss[SUP] 2 [/SUP], Michael Joannidis[SUP] 10 [/SUP], Judith Löffler-Ragg[SUP] 11 [/SUP], Ivan Tancevski[SUP] 12 [/SUP]
Affiliations
Abstract
The severity of coronavirus disease 2019 (COVID-19) is related to the presence of comorbidities including metabolic diseases. We herein present data from the longitudinal prospective CovILD trial, and investigate the recovery from COVID-19 in individuals with dysglycemia and dyslipidemia. A total of 145 COVID-19 patients were prospectively followed and a comprehensive clinical, laboratory and imaging assessment was performed at 60, 100, 180, and 360 days after the onset of COVID-19. The severity of acute COVID-19 and outcome at early post-acute follow-up were significantly related to the presence of dysglycemia and dyslipidemia. Still, at long-term follow-up, metabolic disorders were not associated with an adverse pulmonary outcome, as reflected by a good recovery of structural lung abnormalities in both, patients with and without metabolic diseases. To conclude, dyslipidemia and dysglycemia are associated with a more severe course of acute COVID-19 as well as delayed early recovery but do not impair long-term pulmonary recovery.
. 2023 Feb 14;13(1):2599.
doi: 10.1038/s41598-023-29654-1.
Pulmonary recovery from COVID-19 in patients with metabolic diseases: a longitudinal prospective cohort study
Thomas Sonnweber[SUP] #[/SUP][SUP] 1 [/SUP], Philipp Grubwieser[SUP] #[/SUP][SUP] 2 [/SUP], Alex Pizzini[SUP] 2 [/SUP], Anna Boehm[SUP] 2 [/SUP], Sabina Sahanic[SUP] 2 [/SUP], Anna Luger[SUP] 3 [/SUP], Christoph Schwabl[SUP] 3 [/SUP], Gerlig Widmann[SUP] 3 [/SUP], Alexander Egger[SUP] 4 [/SUP], Gregor Hoermann[SUP] 4 5 [/SUP], Ewald Wöll[SUP] 6 [/SUP], Bernhard Puchner[SUP] 2 7 [/SUP], Susanne Kaser[SUP] 8 [/SUP], Igor Theurl[SUP] 2 [/SUP], Manfred Nairz[SUP] 2 [/SUP], Piotr Tymoszuk[SUP] 9 [/SUP], Günter Weiss[SUP] 2 [/SUP], Michael Joannidis[SUP] 10 [/SUP], Judith Löffler-Ragg[SUP] 11 [/SUP], Ivan Tancevski[SUP] 12 [/SUP]
Affiliations
- PMID: 36788324
- DOI: 10.1038/s41598-023-29654-1
Abstract
The severity of coronavirus disease 2019 (COVID-19) is related to the presence of comorbidities including metabolic diseases. We herein present data from the longitudinal prospective CovILD trial, and investigate the recovery from COVID-19 in individuals with dysglycemia and dyslipidemia. A total of 145 COVID-19 patients were prospectively followed and a comprehensive clinical, laboratory and imaging assessment was performed at 60, 100, 180, and 360 days after the onset of COVID-19. The severity of acute COVID-19 and outcome at early post-acute follow-up were significantly related to the presence of dysglycemia and dyslipidemia. Still, at long-term follow-up, metabolic disorders were not associated with an adverse pulmonary outcome, as reflected by a good recovery of structural lung abnormalities in both, patients with and without metabolic diseases. To conclude, dyslipidemia and dysglycemia are associated with a more severe course of acute COVID-19 as well as delayed early recovery but do not impair long-term pulmonary recovery.